secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001576280-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)
--------------------------------------------------------------------------------

- Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).
- Shield screening tests surged to ~38,000 in Q4 (vs 6,400 prior year).
- Preliminary free cash flow: -$54M Q4, -$233M full year.
- Cash and marketable securities ~$1.3B as of Dec 31, 2025.
- Results are preliminary and unaudited; final audited results expected Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000004/0001576280-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000004/gh-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001576280-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer